Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Guardant Health, Inc. (GH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GH at 39.0/100 on a 32-signal composite quality model, placing it at rank #2,164 of 2,961 stocks — the bottom half of the AI-ranked universe. GH scores in the top quartile across revenue growth (90.6). Areas of concern include balance sheet strength (8.3) and free cash flow (12.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Guardant Health, Inc. reports quarterly revenue of $335.0M, net income of $-120.1M, an operating margin of -38.6%. Top institutional holders of GH by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GH trades on the Nasdaq exchange and files with the SEC under CIK 1576280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardant Health, Inc. directly from SEC EDGAR.
AI Quality Score
39.0/100
AI Rank
#2,164
Revenue
$335.0M
Net Income
$-120.1M
Free Cash Flow
$-69.5M
Operating Margin
-38.6%
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $982.0M | $-416.3M | -44.5% |
| FY 2024 | 10-K | $739.0M | $-436.4M | -60.0% |
| FY 2023 | 10-K | $563.9M | $-479.4M | -100.1% |
| FY 2022 | 10-K | $449.5M | $-654.6M | -121.1% |
| FY 2021 | 10-K | $373.7M | $-384.8M | -110.0% |
| FY 2020 | 10-K | $286.7M | — | -88.9% |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| BlackRock | 7,622,935 | $1.1B | 2026-06-30 |
| PRICE T ROWE ASSOCIATES | 6,514,952 | $977.4M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT | 5,755,857 | $863.6M | 2026-06-30 |
| FMR | 5,488,272 | $823.4M | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT | 5,445,785 | $817.0M | 2026-06-30 |
| Invesco Ltd. | 4,429,755 | $664.6M | 2026-06-30 |
| GOLDMAN SACHS GROUP | 3,775,895 | $566.5M | 2026-06-30 |
| TWO SIGMA INVESTMENTS | 3,719,301 | $558.0M | 2026-06-30 |
| LINDEN ADVISORS | 204,330,000 | $514.2M | 2026-06-30 |
| Capital International Investors | 3,399,604 | $510.0M | 2026-06-30 |
13F Pro Quality Score
Rank #2,164 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk